Dr. Xiaofeng Li, PhD
Senior Director, Head of BAS biomarker platform
Dr. Xiaofeng Li is Senior Director and Head of BAS Biomarker Platform, supporting translational science from preclinical research through clinical development, regulatory approval, and market access to patients in need. His expertise spans antibodies, recombinant proteins, peptides, ADCs, AOCs, molecular glues, and other advanced therapeutic modalities. He leads the clinical translational biomarker team across flow cytometry, immunochemistry, and molecular platforms including qPCR and ddPCR. His team has supported 320+ clinical assay development, validation, and transfer programs under cGxP and global regulatory frameworks. Dr. Li holds a PhD from RWTH Aachen University, and completed postdoctoral fellowships at the University of Miami and Harvard Medical School. Before WuXi AppTec, he held translational biomarker and bioanalytical roles at Biogen, Sanofi, and Aurion Biotech.